FDA announces a new Sentinel System contract, affirming its commitment to harnessing real-world data to improve the safety and effectiveness of drugs

27 September 2019 - Today, the U.S. FDA is announcing an award granting a new five-year contract for the Sentinel ...

Read more →

Health Canada approves Tecentriq in combination with chemotherapy (nab-paclitaxel) as first immunotherapy treatment for aggressive form of breast cancer

27 September 2019 - New approval provides patients with PD-L1 positive, metastatic triple-negative breast cancer with an additional treatment option that ...

Read more →

Intercept submits new drug application to the U.S. FDA for obeticholic acid in patients with fibrosis due to NASH

27 September 2019 - NDA supported by positive interim analysis results from REGENERATE Phase 3 study demonstrating OCA’s improvement of liver ...

Read more →

FDA approves first treatment for children with rare diseases that cause inflammation of small blood vessels

27 September 2019 - The U.S. FDA today approved Rituxan (rituximab) injection to treat granulomatosis with polyangiitis (GPA) and microscopic polyangiitis ...

Read more →

FDA clarifies how it will regulate digital health and artificial intelligence

26 September 2019 - The FDA has issued new guidelines on how it will regulate mobile health software and products ...

Read more →

IntelGenx announces resubmission of Rizaport new drug application

26 September 2019 - IntelGenx today announced that it has resubmitted its 505(b)(2) new drug application for Rizaport VersaFilm for the ...

Read more →

Inventiva receives FDA fast track designation for lead asset lanifibranor in NASH

26 September 2019 - Designation is intended to facilitate the development and expedite the regulatory review of lanifibranor for the treatment ...

Read more →

Change of name of liposomal medicines at high risk of medication errors

26 September 2019 - Marketing authorisation holders of medicines containing liposomal drug delivery systems are requested to submit a variation ...

Read more →

FDA begins reorganisation phase of modernisation efforts to increase efficiency and further support new drug development

26 September 2019 - Today, the U.S. FDA’s Center for Drug Evaluation and Research (CDER) announced that the reorganization of certain ...

Read more →

FDA approves daratumumab for transplant eligible multiple myeloma

26 September 2019 -  The FDA has today approved daratumumab (Darzalex, Janssen) for adult patients with multiple myeloma in combination ...

Read more →

FDA approves treatment for adults and children with all genotypes of hepatitis C and compensated cirrhosis that shortens duration of treatment to eight weeks

26 September 2019 - The U.S. FDA today expanded the approval of Mavyret (glecaprevir and pibrentasvir) tablets for an eight week ...

Read more →

Ipsen announces FDA approval of Dysport (abobotulinumtoxinA) for the treatment of upper limb spasticity in children, excluding cerebral palsy

26 September 2019 - Dysport is the first and only FDA approved botulinum toxin for treatment of both paediatric upper and ...

Read more →

Acacia Pharma announces new Barhemsys PDUFA target date of 26 February 2020

26 September 2019 - This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation ...

Read more →

Achillion receives breakthrough therapy designation from FDA for danicopan for treatment of paroxysmal nocturnal hemoglobinuria

25 September 2019 - Achillion Pharmaceuticals today announced that the U.S. FDA has granted breakthrough therapy designation for danicopan (ACH-4471) for ...

Read more →

TGA approves drug to fight ovarian cancer

26 September 2019 - Some women diagnosed with ovarian cancer could have their survival rates significantly increased after the Therapeutic ...

Read more →